What is William Blair's Forecast for MaxCyte Q2 Earnings?

MaxCyte, Inc. (NASDAQ:MXCT - Free Report) - William Blair cut their Q2 2025 earnings per share estimates for MaxCyte in a report issued on Thursday, May 8th. William Blair analyst M. Larew now anticipates that the company will earn ($0.11) per share for the quarter, down from their previous forecast of ($0.09). The consensus estimate for MaxCyte's current full-year earnings is ($0.42) per share. William Blair also issued estimates for MaxCyte's Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.42) EPS, Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.39) EPS.

MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.10). MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. The business had revenue of $10.39 million for the quarter, compared to analysts' expectations of $9.05 million.

MXCT has been the subject of a number of other reports. Stifel Nicolaus cut their price objective on shares of MaxCyte from $11.00 to $9.00 and set a "buy" rating for the company in a research report on Wednesday, March 12th. BTIG Research set a $6.00 price target on shares of MaxCyte and gave the company a "buy" rating in a report on Wednesday, March 12th.

MaxCyte Stock Performance

Shares of MXCT remained flat at $2.20 during midday trading on Monday. The stock had a trading volume of 1,325,247 shares, compared to its average volume of 548,102. MaxCyte has a 12-month low of $2.15 and a 12-month high of $5.26. The firm has a market cap of $233.90 million, a price-to-earnings ratio of -6.47 and a beta of 1.38. The stock's 50 day moving average is $2.78 and its 200-day moving average is $3.60.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC lifted its position in MaxCyte by 123.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,564 shares of the company's stock valued at $31,000 after purchasing an additional 4,173 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of MaxCyte during the 4th quarter worth $56,000. Kwmg LLC purchased a new position in MaxCyte in the first quarter worth $40,000. Prudential Financial Inc. purchased a new position in MaxCyte in the fourth quarter worth $65,000. Finally, Catalyst Funds Management Pty Ltd purchased a new stake in MaxCyte during the fourth quarter valued at about $74,000. Hedge funds and other institutional investors own 68.81% of the company's stock.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.